KDR and adrenal cortex carcinoma: VEGFR inhibitors are a potential systemic therapy alternative for recurrent/metastatic ACC [40, 41, 42, 43, 44, 45, 46]; however, while VEGFR inhibitors produce high disease stabilization rates, the ORR remain close to 6% [5, 47].